H-Arg(Pbf)-OtBu · HCl

• CAT Number: M144265
• CAS Number: 1217317-67-3
• Molecular Formula: C23H39ClN4O5S
• Molecular Weight: 519.09
• Purity: ≥95%
• Storage: Room temperature
• Related CAS: 1207974-52-4
• IUPAC Name: tert-butyl (2S)-2-amino-5-[[amino-[(2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]pentanoate;hydrochloride
• InChI: InChI=1S/C23H38N4O5S.ClH/c1-13-14(2)19(15(3)16-12-23(7,8)31-18(13)16)33(29,30)27-21(25)26-11-9-10-17(24)20(28)32-22(4,5)6;/h17H,9-12,24H2,1-8H3,(H3,25,26,27);1H/t17-;/m0./s1
• InChIKey: WKCFBQLFXPHSBQ-LMOVPXPDSA-N
• SMILES: CC1=C(C(=C(C2=C1OC(C2)(C)C)C)S(=O)(=O)NC(=NCCCC(C(=O)OC(C)(C)C)N)N)C.Cl

H-Arg(Pbf)-OtBu · HCl（Cat No.:M144265） is a chemical compound used in peptide synthesis. It consists of arginine (Arg) with the side chain protected by a 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group and the C-terminus protected by a test-butoxy carbonyl (OtBu) group, all linked to a hydrochloride (HCl) salt. This compound is commonly used as a building block in the solid-phase synthesis of peptides due to its stability and ability to selectively react with other amino acids. The Pbf and OtBu groups protect the functional groups of arginine during peptide assembly, preventing side reactions and ensuring the desired sequence is obtained.

Reference

[1]. Groll, M., Götz, M., Kaiser, M., Weyher, E. and Moroder, L.,
Supplemental Data TMC-95-Based Inhibitor Design Provides Evidence for the Catalytic Versatility of the Proteasome.

[2]. Yajima, S., Shionoya, H., Akagi, T. and Hamasaki, K., 2006.
Neamine derivatives having a nucleobase with a lysine or an arginine as a linker, their synthesis and evaluation as potential inhibitors for HIV TAR–Tat.
Abstract: Neamine derivatives bearing a nucleobase, adenine, cytosine, guanine or thymine with a lysine or an arginine as a linker have been synthesized and its potential as the inhibitor for HIV TAR–Tat interaction examined. Among them, modified neamine having an arginine-nucleobase showed a higher inhibition than that of the one having a lysine-nucleobase. The difference of the nucleobase anchor did not characterize inhibition specificity. Also, stereochemistry of the amino acid in the compounds causes no difference in the inhibition for TAR–Tat.
Bioorganic & medicinal chemistry, 14(8), pp.2799-2809.